{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:35:41Z","timestamp":1790688941596,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"crossref","award":["2018-02532"],"award-info":[{"award-number":["2018-02532"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European research council","award":["681712"],"award-info":[{"award-number":["681712"]}]},{"name":"Swedish State Support for Clinical Research","award":["ALFGBG-720931"],"award-info":[{"award-number":["ALFGBG-720931"]}]},{"name":"Frimurarestiftelsen"},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["201809-2016862"],"award-info":[{"award-number":["201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Alzheimer\u2019s disease (AD) is the most common form of age-related neurodegenerative diseases. Cerebral deposition of A\u03b2 peptides, especially A\u03b242, is considered the major neuropathological hallmark of AD and the putative cause of AD-related neurotoxicity. A\u03b2 peptides are produced by sequential proteolytic processing of APP, with \u03b2-secretase (BACE) being the initiating enzyme. Therefore, BACE has been considered an attractive therapeutic target in AD research and several BACE inhibitors have been tested in clinical trials, but so far, all have had negative outcomes or even led to worsening of cognitive function. AD can be triggered by A\u03b2 years before the first symptoms appear and one reason for the failures could be that the clinical trials were initiated too late in the disease process. Another possible explanation could be that BACE inhibition alters physiological APP processing in a manner that impairs synaptic function, causing cognitive deterioration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The aim of this study was to investigate if partial BACE inhibition, mimicking the putative protective effect of the Icelandic mutation in the <jats:italic>APP<\/jats:italic> gene, could reduce A\u03b2 generation without affecting synaptic transmission. To investigate this, we used an optical electrophysiology platform, in which effects of compounds on synaptic transmission in cultured neurons can be monitored. We employed this method on primary cortical rat neuronal cultures treated with three different BACE inhibitors (BACE inhibitor IV, LY2886721, and lanabecestat) and monitored A\u03b2 secretion into the cell media.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that all three BACE inhibitors tested decreased synaptic transmission at concentrations leading to significantly reduced A\u03b2 secretion. However, low-dose BACE inhibition, resulting in less than a 50% decrease in A\u03b2 secretion, did not affect synaptic transmission for any of the inhibitors tested.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results indicate that A\u03b2 production can be reduced by up to 50%, a level of reduction of relevance to the protective effect of the Icelandic mutation, without causing synaptic dysfunction. We therefore suggest that future clinical trials aimed at prevention of A\u03b2 build-up in the brain should aim for a moderate CNS exposure of BACE inhibitors to avoid side effects on synaptic function.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-020-00635-0","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T18:04:28Z","timestamp":1590516268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Partial reduction of amyloid \u03b2 production by \u03b2-secretase inhibitors does not decrease synaptic transmission"],"prefix":"10.1186","volume":"12","author":[{"given":"Tugce Munise","family":"Satir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3816-7474","authenticated-orcid":false,"given":"Lotta","family":"Agholme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Karila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Illes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"issue":"5","key":"635_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","volume":"15","author":"B Winblad","year":"2016","unstructured":"Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer\u2019s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455\u2013532.","journal-title":"Lancet Neurol"},{"issue":"10","key":"635_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci. 1991;12(10):383\u20138.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"635_CR3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8(6):595\u2013608.","journal-title":"EMBO Mol Med"},{"issue":"6","key":"635_CR4","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.neurobiolaging.2009.06.002","volume":"32","author":"E Portelius","year":"2011","unstructured":"Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011;32(6):1090\u20138.","journal-title":"Neurobiol Aging"},{"issue":"7","key":"635_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","volume":"9","author":"F Mangialasche","year":"2010","unstructured":"Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer\u2019s disease: clinical trials and drug development. Lancet Neurol. 2010;9(7):702\u201316.","journal-title":"Lancet Neurol"},{"issue":"10","key":"635_CR6","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/nm.3365","volume":"19","author":"K Blennow","year":"2013","unstructured":"Blennow K, Zetterberg H, Haass C, Finucane T. Semagacestat\u2019s fall: where next for AD therapies? Nat Med. 2013;19(10):1214\u20135.","journal-title":"Nat Med"},{"issue":"10","key":"635_CR7","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1073\/pnas.0205689101","volume":"101","author":"R Li","year":"2004","unstructured":"Li R, Lindholm K, Yang L-B, Yue X, Citron M, Yan R, et al. Amyloid \u03b2 peptide load is correlated with increased \u03b2-secretase activity in sporadic Alzheimer\u2019s disease patients. Proc Natl Acad Sci U S A. 2004;101(10):3632\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"635_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0002-9440(10)63159-8","volume":"164","author":"H Fukumoto","year":"2004","unstructured":"Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. \u03b2-Secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol. 2004;164(2):719\u201325.","journal-title":"Am J Pathol"},{"issue":"8","key":"635_CR9","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1001\/archneur.65.8.1102","volume":"65","author":"H Zetterberg","year":"2008","unstructured":"Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008;65(8):1102\u20137.","journal-title":"Arch Neurol"},{"issue":"12","key":"635_CR10","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/nm1295-1291","volume":"1","author":"C Haass","year":"1995","unstructured":"Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, et al. The Swedish mutation causes early-onset Alzheimer\u2019s disease by \u03b2-secretase cleavage within the secretory pathway. Nat Med. 1995;1(12):1291\u20136.","journal-title":"Nat Med"},{"issue":"7409","key":"635_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature. 2012;488(7409):96\u20139.","journal-title":"Nature."},{"issue":"1","key":"635_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ana.24969","volume":"82","author":"H Martiskainen","year":"2017","unstructured":"Martiskainen H, Herukka S-K, Stan\u010d\u00e1kov\u00e1 A, Paananen J, Soininen H, Kuusisto J, et al. Decreased plasma \u03b2-amyloid in the Alzheimer\u2019s disease APP A673T variant carriers. Ann Neurol. 2017;82(1):128\u201332.","journal-title":"Ann Neurol"},{"issue":"4","key":"635_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.05.1900","volume":"8","author":"M Forman","year":"2012","unstructured":"Forman M, Palcza J, Tseng J, Leempoels J, Ramael S, Han D, et al. The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid A\u03b2 peptides in healthy subjects following single- and multiple-dose administration. Alzheimers Dement. 2012;8(4):P704.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"635_CR14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.biopsych.2018.04.022","volume":"84","author":"K Zhu","year":"2018","unstructured":"Zhu K, Peters F, Filser S, Herms J. Consequences of pharmacological BACE inhibition on synaptic structure and function. Biol Psychiatry. 2018;84(7):478\u201387.","journal-title":"Biol Psychiatry"},{"issue":"6393","key":"635_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/359322a0","volume":"359","author":"C Haass","year":"1992","unstructured":"Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, et al. Amyloid \u03b2-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359(6393):322\u20135.","journal-title":"Nature."},{"issue":"2","key":"635_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0304-3940(96)13087-1","volume":"217","author":"Y Luo","year":"1996","unstructured":"Luo Y, Sunderland T, Roth GS, Wolozin B. Physiological levels of \u03b2-amyloid peptide promote PC12 cell proliferation. Neurosci Lett. 1996;217(2):125\u20138.","journal-title":"Neurosci Lett"},{"issue":"3","key":"635_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/cdd.2008.94","volume":"16","author":"Y Chen","year":"2009","unstructured":"Chen Y, Dong C. A\u03b240 promotes neuronal cell fate in neural progenitor cells. Cell Death Differ. 2009;16(3):386\u201394.","journal-title":"Cell Death Differ"},{"issue":"6","key":"635_CR18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0896-6273(03)00124-7","volume":"37","author":"F Kamenetz","year":"2003","unstructured":"Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al. APP processing and synaptic function. Neuron. 2003;37(6):925\u201337.","journal-title":"Neuron."},{"issue":"2","key":"635_CR19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/JAD-2010-1230","volume":"19","author":"JE Morley","year":"2010","unstructured":"Morley JE, Farr SA, Banks WA, Johnson SN, Yamada KA, Xu L. A physiological role for amyloid-beta protein:enhancement of learning and memory. J Alzheimers Dis. 2010;19(2):441\u20139.","journal-title":"J Alzheimers Dis"},{"issue":"18, Part A","key":"635_CR20","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1016\/j.jmb.2018.07.016","volume":"430","author":"B Sidders","year":"2018","unstructured":"Sidders B, Karlsson A, Kitching L, Torella R, Karila P, Phelan A. Network-based drug discovery: coupling network pharmacology with phenotypic screening for neuronal excitability. J Mol Biol. 2018;430(18, Part A):3005\u201315.","journal-title":"J Mol Biol."},{"issue":"2","key":"635_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1087057113505905","volume":"19","author":"B Chan","year":"2014","unstructured":"Chan B, Cottrell JR, Li B, Larson KC, Ashford CJ, Levenson JM, et al. Development of a high-throughput AlphaScreen assay for modulators of synapsin I phosphorylation in primary neurons. J Biomol Screen. 2014;19(2):205\u201314.","journal-title":"J Biomol Screen"},{"issue":"2","key":"635_CR22","doi-asserted-by":"publisher","first-page":"e31084","DOI":"10.1371\/journal.pone.0031084","volume":"7","author":"N Mattsson","year":"2012","unstructured":"Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, et al. BACE1 inhibition induces a specific cerebrospinal fluid \u03b2-amyloid pattern that identifies drug effects in the central nervous system. PLoS One. 2012;7(2):e31084.","journal-title":"PLoS One"},{"issue":"3","key":"635_CR23","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1523\/JNEUROSCI.4129-14.2015","volume":"35","author":"PC May","year":"2015","unstructured":"May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015;35(3):1199\u2013210.","journal-title":"J Neurosci"},{"issue":"5, Supplement","key":"635_CR24","doi-asserted-by":"publisher","first-page":"S411","DOI":"10.1016\/j.jalz.2013.11.004","volume":"10","author":"DK Lahiri","year":"2014","unstructured":"Lahiri DK, Maloney B, Long JM, Greig NH. Lessons from a BACE1 inhibitor trial: off-site but not off base. Alzheimer\u2019s Dementia. 2014;10(5, Supplement):S411\u20139.","journal-title":"Alzheimer\u2019s Dementia."},{"issue":"11","key":"635_CR25","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/jcph.950","volume":"57","author":"K Sakamoto","year":"2017","unstructured":"Sakamoto K, Matsuki S, Matsuguma K, Yoshihara T, Uchida N, Azuma F, et al. BACE1 inhibitor lanabecestat (AZD3293) in a phase 1 study of healthy Japanese subjects: pharmacokinetics and effects on plasma and cerebrospinal fluid Abeta peptides. J Clin Pharmacol. 2017;57(11):1460\u201371.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"635_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","volume":"77","author":"Alette M. Wessels","year":"2020","unstructured":"Wessels AM, Tariot PN, Zimmer JA, Selzler KJ, Bragg SM, Andersen SW, et al. Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials. JAMA Neurol. 2019;77(2):199\u2013209.","journal-title":"JAMA Neurology"},{"issue":"26","key":"635_CR27","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.1021\/jm049379g","volume":"47","author":"SJ Stachel","year":"2004","unstructured":"Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, et al. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J Med Chem. 2004;47(26):6447\u201350.","journal-title":"J Med Chem"},{"key":"635_CR28","unstructured":"Neff R, Lindwall-Blom C, J\u00e4gervall \u00c5, Balana B, Karlsson M, Karila P, et al., Development of a moderate throughput assay to detect novel modulators of synaptic efficacy in neuronal cultures in Society for Neuroscience 2015: Washington, DC."},{"issue":"7573","key":"635_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature14864","volume":"526","author":"M Willem","year":"2015","unstructured":"Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S, et al. Eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature. 2015;526(7573):443\u20137.","journal-title":"Nature."},{"issue":"11","key":"635_CR30","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/13543784.2019.1683160","volume":"28","author":"BP Imbimbo","year":"2019","unstructured":"Imbimbo BP, Watling M. Investigational BACE inhibitors for the treatment of Alzheimer\u2019s disease. Expert Opin Investig Drugs. 2019;28(11):967\u201375.","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"635_CR31","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.biopsych.2014.10.013","volume":"77","author":"S Filser","year":"2015","unstructured":"Filser S, Ovsepian SV, Masana M, Blazquez-Llorca L, Brandt Elvang A, Volbracht C, et al. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol Psychiatry. 2015;77(8):729\u201339.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"635_CR32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.biopsych.2016.12.023","volume":"83","author":"K Zhu","year":"2018","unstructured":"Zhu K, Xiang X, Filser S, Marinkovi\u0107 P, Dorostkar MM, Crux S, et al. Beta-site amyloid precursor protein cleaving enzyme 1 inhibition impairs synaptic plasticity via seizure protein 6. Biol Psychiatry. 2018;83(5):428\u201337.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"635_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3233\/JAD-160806","volume":"56","author":"Y Kamikubo","year":"2017","unstructured":"Kamikubo Y, Takasugi N, Niisato K, Hashimoto Y, Sakurai T. Consecutive analysis of BACE1 function on developing and developed neuronal cells. J Alzheimer\u2019s Disease. 2017;56(2):641\u201353.","journal-title":"J Alzheimer\u2019s Disease"},{"issue":"3","key":"635_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092279","volume":"9","author":"H Wang","year":"2014","unstructured":"Wang H, Megill A, Wong PC, Kirkwood A, Lee H-K. Postsynaptic target specific synaptic dysfunctions in the CA3 area of BACE1 knockout mice. PLoS One. 2014;9(3):e92279.","journal-title":"PLoS One"},{"issue":"50","key":"635_CR35","doi-asserted-by":"publisher","first-page":"11693","DOI":"10.1523\/JNEUROSCI.2766-05.2005","volume":"25","author":"FM Laird","year":"2005","unstructured":"Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-\u03b2 amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25(50):11693\u2013709.","journal-title":"J Neurosci"},{"issue":"3","key":"635_CR36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.trci.2016.08.001","volume":"2","author":"M Timmers","year":"2016","unstructured":"Timmers M, Van Broeck B, Ramael S, Slemmon J, De Waepenaert K, Russu A, et al. Profiling the dynamics of CSF and plasma A\u03b2 reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimers Dement. 2016;2(3):202\u201312.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"635_CR37","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1016\/S0021-9258(17)42055-2","volume":"269","author":"SB Roberts","year":"1994","unstructured":"Roberts SB, Ripellino JA, Ingalls KM, Robakis NK, Felsenstein KM. Non-amyloidogenic cleavage of the beta-amyloid precursor protein by an integral membrane metalloendopeptidase. J Biol Chem. 1994;269(4):3111\u20136.","journal-title":"J Biol Chem"},{"key":"635_CR38","doi-asserted-by":"publisher","unstructured":"Mockett BG, Richter M, Abraham WC, and M\u00fcller UC. Therapeutic potential of secreted amyloid precursor protein APPs\u03b1. Front Molecular Neurosci. 2017;10(30):1\u201314. https:\/\/doi.org\/10.3389\/fnmol.2017.00030eCollection%202017.","DOI":"10.3389\/fnmol.2017.00030eCollection%202017"},{"issue":"41","key":"635_CR39","doi-asserted-by":"publisher","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","volume":"29","author":"R Vassar","year":"2009","unstructured":"Vassar R, Kovacs DM, Yan R, Wong PC. The \u03b2-secretase enzyme BACE in health and Alzheimer\u2019s disease: regulation, cell biology, function, and therapeutic potential. J Neurosci. 2009;29(41):12787\u201394.","journal-title":"J Neurosci"},{"key":"635_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40035-017-0093-5","volume":"6","author":"B Das","year":"2017","unstructured":"Das B, Yan R. Role of BACE1 in Alzheimer\u2019s synaptic function. Transl Neurodegener. 2017;6:23.","journal-title":"Transl Neurodegener"},{"issue":"46","key":"635_CR41","doi-asserted-by":"publisher","first-page":"38408","DOI":"10.1074\/jbc.M112.415505","volume":"287","author":"B Hitt","year":"2012","unstructured":"Hitt B, Riordan SM, Kukreja L, Eimer WA, Rajapaksha TW, Vassar R. \u03b2-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J Biol Chem. 2012;287(46):38408\u201325.","journal-title":"J Biol Chem"},{"issue":"2","key":"635_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.semcdb.2009.01.003","volume":"20","author":"M Willem","year":"2009","unstructured":"Willem M, Lammich S, Haass C. Function, regulation and therapeutic properties of \u03b2-secretase (BACE1). Semin Cell Dev Biol. 2009;20(2):175\u201382.","journal-title":"Semin Cell Dev Biol"},{"issue":"2","key":"635_CR43","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2174\/156720512799361637","volume":"9","author":"D Fleck","year":"2012","unstructured":"Fleck D, Garratt AN, Haass C, Willem M. BACE1 dependent neuregulin processing: review. Curr Alzheimer Res. 2012;9(2):178\u201383.","journal-title":"Curr Alzheimer Res"},{"key":"635_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.mcn.2017.10.009","volume":"85","author":"L Agholme","year":"2017","unstructured":"Agholme L, Clarin M, Gkanatsiou E, Kettunen P, Chebli J, Brinkmalm G, et al. Low-dose gamma-secretase inhibition increases secretion of Abeta peptides and intracellular oligomeric Abeta. Mol Cell Neurosci. 2017;85:211\u20139.","journal-title":"Mol Cell Neurosci"},{"issue":"2","key":"635_CR45","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1124\/jpet.106.110700","volume":"319","author":"TA Lanz","year":"2006","unstructured":"Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, et al. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther. 2006;319(2):924\u201333.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"635_CR46","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","volume":"27","author":"PN Lacor","year":"2007","unstructured":"Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer\u2019s disease. J Neurosci. 2007;27(4):796\u2013807.","journal-title":"J Neurosci"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00635-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-020-00635-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00635-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T23:22:24Z","timestamp":1621984944000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00635-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["635"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00635-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"18 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures for experiments were performed in accordance with the ethical committee in Gothenburg (ethical permit 5.8.18-11305\/2018) and followed the guidelines of the Swedish National Board for Laboratory Animals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HZ has served at scientific advisory boards for Samumed, CogRx, Roche Diagnostics, Denali, and Wave, has given lectures in symposia sponsored by Fujirebio, AlzeCure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. AK, MK, PK, and SI were all employed by Cellectricon AB at the time for the experiments. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}